<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159870</url>
  </required_header>
  <id_info>
    <org_study_id>RIFA01</org_study_id>
    <nct_id>NCT04159870</nct_id>
  </id_info>
  <brief_title>Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis</brief_title>
  <official_title>Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedali Riuniti di Foggia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedali Riuniti di Foggia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background&#xD;
&#xD;
      Prophylaxis of SBP is indicated in three high-risk populations: patients with acute&#xD;
      gastrointestinal hemorrhage, patients with low total protein content in ascitic fluid, and&#xD;
      patients with a previous history of SBP (secondary prophylaxis).&#xD;
&#xD;
      Selective intestinal decontamination with norfloxacin, a quinolone with relatively poor&#xD;
      gastrointestinal absorption and with antibacterial activity against GNB, is the most commonly&#xD;
      used regimen, but several concerns have been recently raised in this regard.&#xD;
&#xD;
      A recent network meta-analysis published by the investigators showed that rifaximin&#xD;
      determines interesting results in this setting but needs to be tested in further trials.&#xD;
&#xD;
      Given its favorable safety profile and the relatively low cost, rifaximin could represent the&#xD;
      antibiotic of choice in long-term prophylaxis.&#xD;
&#xD;
      Study Objective To establish the prophylactic efficacy, of rifaximin as compared to&#xD;
      norfloxacin in cirrhotic patients with low protein content in the ascitic fluid.&#xD;
&#xD;
      Protocol design Phase III, two-arms, open-label, multi-center, randomized controlled trial.&#xD;
&#xD;
      Trial population Patients with cirrhosis and ascites and with low protein content in the&#xD;
      ascitic fluid (≤1.5 g/dL) and with deteriorated liver function (Child-Pugh score ≥B9, serum&#xD;
      bilirubin level ≥3 mg/dL) or impaired renal function (creatinine ≥1.2 mg/dL blood urea&#xD;
      nitrogen level ≥25 mg/dL or hyponatremia ≤130 milliequivalent [mEq]/L)&#xD;
&#xD;
      Protocol Treatments&#xD;
&#xD;
        -  The Treatment arm will undergo rifaximin 1200 mg/day in 3 doses.&#xD;
&#xD;
        -  The Control arm will undergo norfloxacin 400 mg 1/die for 6 months&#xD;
&#xD;
      Primary Endpoint Prevention of spontaneous bacterial peritonitis episodes.&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
        -  Prevention of mortality (both all-cause and liver-related mortality)&#xD;
&#xD;
        -  Preventions of hepatorenal syndrome&#xD;
&#xD;
        -  Prevention of other infections&#xD;
&#xD;
        -  Adverse events&#xD;
&#xD;
      Sample size and study duration It will be planned to enroll 322 patients (161 per arms)&#xD;
      within 18 months. A minimum follow up of 6 months from the last patient recruited will be&#xD;
      required.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Spontaneous bacterial peritonitis (SBP) is a commonly observed and severe complication in&#xD;
      patients with cirrhosis and ascites, with a reported prevalence ranging from 10% to 25% in&#xD;
      hospitalized cirrhotic patients1.&#xD;
&#xD;
      Given the high mortality rate and the risk of developing hepato-renal syndrome (HRS),&#xD;
      prophylaxis of SBP is indicated particularly in three high-risk populations: patients with&#xD;
      acute gastrointestinal hemorrhage, patients with low total protein content in ascitic fluid,&#xD;
      and patients with a previous history of SBP (secondary prophylaxis)2.&#xD;
&#xD;
      The ideal prophylactic agent should be safe, affordable, and effective particularly against&#xD;
      anaerobic bacteria translocating from the gut as most episodes of SBP are thought to result&#xD;
      from the translocation of enteric Gram-negative bacilli (GNB)3.&#xD;
&#xD;
      Selective intestinal decontamination with norfloxacin, a quinolone with relatively poor&#xD;
      gastrointestinal absorption and with antibacterial activity against GNB, is the most commonly&#xD;
      used regimen4, but several concerns have been recently raised in this regard. In fact, the&#xD;
      epidemiology of bacterial infections in cirrhosis is evolving with an increasing incidence of&#xD;
      infections caused by quinolone-resistant bacteria5; moreover, primary prophylaxis in&#xD;
      low-protein ascitic patients requires long-term antibiotic regimens (whose exact duration is&#xD;
      still matter of debate), hence less expensive and better tolerated agents such as rifaximin&#xD;
      have been tested with conflicting results6.&#xD;
&#xD;
      A recent network meta-analysis published by the investigators showed that rifaximin&#xD;
      determines interesting results in this setting but needs to be tested in further trials7.&#xD;
&#xD;
      Given its favorable safety profile and the relatively low cost, rifaximin could represent the&#xD;
      antibiotic of choice in long-term prophylaxis.&#xD;
&#xD;
      Study Objective To establish the prophylactic efficacy, of rifaximin as compared to&#xD;
      norfloxacin in cirrhotic patients with low protein content in the ascitic fluid.&#xD;
&#xD;
      Protocol design Phase III, two-arms, open-label, multi-center, randomized controlled trial.&#xD;
&#xD;
      Trial population Patients with cirrhosis and ascites and with low protein content in the&#xD;
      ascitic fluid (≤1.5 g/dL) and with deteriorated liver function (Child-Pugh score ≥B9, serum&#xD;
      bilirubin level ≥3 mg/dL) or impaired renal function (creatinine ≥1.2 mg/dL blood urea&#xD;
      nitrogen level ≥25 mg/dL or hyponatremia ≤130 mEq/L)&#xD;
&#xD;
      Protocol Treatments&#xD;
&#xD;
        -  The Treatment arm will undergo rifaximin 1200 mg/day in 3 doses.&#xD;
&#xD;
        -  The Control arm will undergo norfloxacin 400 mg 1/die for 6 months&#xD;
&#xD;
      Protocol&#xD;
&#xD;
      Baseline evaluation will include history and physical examination, liver and renal tests,&#xD;
      ascitic fluid analysis and culture, fresh urine sediment, and abdominal ultrasonography.&#xD;
      Treatment will start immediately after randomization. Follow-up visits will be performed&#xD;
      every 4 weeks. Treatment compliance will be assessed by interviewing the patient and by&#xD;
      tablet count at each visit. A patient will be considered noncompliant when the study&#xD;
      medication will not be taken for 7 days or more, or will fail to take more than 20 % of their&#xD;
      pills or miss two or more visits.&#xD;
&#xD;
      Medications will be interrupted when patients develop an episode of SBP (ascitic fluid&#xD;
      neutrophil count[ 250 cell/ml with or without clinical evidence), or have upper&#xD;
      gastrointestinal (GIT) bleeding or receive a liver transplant.&#xD;
&#xD;
      Diagnostic paracentesis will be performed when clinically indicated. Diagnosis of spontaneous&#xD;
      bacteremia, SBP, urinary infection, and other infections will be made by biological fluid&#xD;
      cultures and analysis; type-1 and type-2 HRS will be diagnosed according to the criteria of&#xD;
      the International Ascites Club. Spontaneous bacteremia and SBP will be treated with&#xD;
      ceftriaxone.&#xD;
&#xD;
      Primary Endpoint Prevention of spontaneous bacterial peritonitis episodes.&#xD;
&#xD;
      Secondary Endpoints&#xD;
&#xD;
        -  Prevention of mortality (both all-cause and liver-related mortality)&#xD;
&#xD;
        -  Preventions of hepatorenal syndrome&#xD;
&#xD;
        -  Prevention of other infections&#xD;
&#xD;
        -  Adverse events&#xD;
&#xD;
      Sample size and study duration It will be planned to enroll 322 patients (161 per arms)&#xD;
      within 18 months. A minimum follow up of 6 months from the last patient recruited will be&#xD;
      required.&#xD;
&#xD;
      Treatment strategy Patients complying with the eligibility criteria will be randomized in a&#xD;
      1:1 fashion to receive rifaximin 1200 mg/day or norfloxacin 400 mg/day. No cross-over will be&#xD;
      allowed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of Spontaneous Bacterial Peritonitis</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of episodes of spontaneous bacterial peritonitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of mortality</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of deaths observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of hepatorenal syndrome</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of hepatorenal syndrome episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of other infections</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of other infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifaximin 1200 mg/day in 3 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norfloxacin 400 mg/day in one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin pills 400 mg x 3/day</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norfloxacin</intervention_name>
    <description>Norlfloxacin 400 mg 1 pill/day</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with cirrhosis and ascites and with low protein content in the ascitic&#xD;
             fluid (≤1.5 g/dL) and with deteriorated liver function (Child-Pugh score ≥B9, serum&#xD;
             bilirubin level ≥3 mg/dL) or impaired renal function (creatinine ≥1.2 mg/dL blood urea&#xD;
             nitrogen level ≥25 mg/dL or hyponatremia ≤130 mEq/L)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years&#xD;
&#xD;
          -  Previous history of SBP&#xD;
&#xD;
          -  Previous use of antibiotics within the previous two weeks&#xD;
&#xD;
          -  Previous GIT bleeding within one month&#xD;
&#xD;
          -  Resolving ascites for one month after diuretic therapy&#xD;
&#xD;
          -  Liver malignancy, organic renal disease&#xD;
&#xD;
          -  Human immunodeficiency virus infection&#xD;
&#xD;
          -  Known hypersensitivity to planned drugs&#xD;
&#xD;
          -  Refusal to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedali Riuniti Foggia</name>
      <address>
        <city>Foggia</city>
        <zip>71122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002 Jan;35(1):140-8.</citation>
    <PMID>11786970</PMID>
  </results_reference>
  <results_reference>
    <citation>European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1. Review.</citation>
    <PMID>20633946</PMID>
  </results_reference>
  <results_reference>
    <citation>Piano S, Brocca A, Mareso S, Angeli P. Infections complicating cirrhosis. Liver Int. 2018 Feb;38 Suppl 1:126-133. doi: 10.1111/liv.13645. Review.</citation>
    <PMID>29427501</PMID>
  </results_reference>
  <results_reference>
    <citation>Soriano G, Guarner C, Tomás A, Villanueva C, Torras X, González D, Sainz S, Anguera A, Cussó X, Balanzó J, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology. 1992 Oct;103(4):1267-72.</citation>
    <PMID>1397884</PMID>
  </results_reference>
  <results_reference>
    <citation>Aparicio JR, Such J, Pascual S, Arroyo A, Plazas J, Girona E, Gutiérrez A, de Vera F, Palazón JM, Carnicer F, Pérez-Mateo M. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol. 1999 Aug;31(2):277-83.</citation>
    <PMID>10453941</PMID>
  </results_reference>
  <results_reference>
    <citation>Menshawy A, Mattar O, Barssoum K, AboEl-Naga AM, Salim HM, Mohamed AMF, Elgebaly A, Abd-Elsalam S. Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis. Curr Drug Targets. 2019;20(4):380-387. doi: 10.2174/1389450119666180924145156.</citation>
    <PMID>30246636</PMID>
  </results_reference>
  <results_reference>
    <citation>Facciorusso A, Papagiouvanni I, Cela M, Buccino VR, Sacco R. Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis. Liver Int. 2019 Aug;39(8):1448-1458. doi: 10.1111/liv.14109. Epub 2019 Apr 25.</citation>
    <PMID>30920712</PMID>
  </results_reference>
  <results_reference>
    <citation>Goel A, Rahim U, Nguyen LH, Stave C, Nguyen MH. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis. Aliment Pharmacol Ther. 2017 Dec;46(11-12):1029-1036. doi: 10.1111/apt.14361. Epub 2017 Oct 9. Review.</citation>
    <PMID>28994123</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedali Riuniti di Foggia</investigator_affiliation>
    <investigator_full_name>Antonio Facciorusso</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Norfloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

